🇺🇸 umbilical cord-mesenchymal stem cells in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 7

Most-reported reactions

1. Bronchitis — 1 report (14.29%)
2. Gait Disturbance — 1 report (14.29%)
3. Illness — 1 report (14.29%)
4. Joint Swelling — 1 report (14.29%)
5. Pain In Extremity — 1 report (14.29%)
6. Peripheral Swelling — 1 report (14.29%)
7. Squamous Cell Carcinoma — 1 report (14.29%)

Source database →

Frequently asked questions

Is umbilical cord-mesenchymal stem cells approved in United States?

umbilical cord-mesenchymal stem cells does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for umbilical cord-mesenchymal stem cells in United States?

General Hospital of Shenyang Military Region is the originator. The local marketing authorisation holder may differ — check the official source linked above.